Established Nonalcoholic Fatty Liver Disease

Topline findings from the phase 2a DUET trial showed that Tern Pharmaceuticals’ oral thyroid hormone receptor-beta agonist achieved significant reductions in liver fat content among patients with nonalcoholic steatohepatitis.

CHICAGO — Patients with nonalcoholic fatty liver disease had worse COVID-19-related outcomes compared with infected individuals without NAFLD, according to data presented at Digestive Disease Week.

Consuming at least 20% of daily calories from fast food correlated with an increased risk for nonalcoholic fatty liver disease, with more damaging effects among individuals with underlying metabolic comorbidities.

Topline findings from the phase 3 MAESTRO-NASH trial showed that resmetirom at both 100 mg and 80 mg doses improved resolution of nonalcoholic steatohepatitis without worsening fibrosis, Madrigal Pharmaceuticals announced.

Lean patients with nonalcoholic fatty liver disease were at greater risk for cardiovascular and chronic kidney disease compared with overweight or obese patients, according to a researcher at the Digestive Disease Week 2022 media briefing.

Nonalcoholic fatty liver disease correlated with lower hepatocellular carcinoma surveillance receipt, early-stage detection and poorer survival compared with other HCC etiologies, according to research.

Among patients newly diagnosed with hepatocellular carcinoma, there are significant racial and ethnic differences in barriers to care, according to survey results published in Clinical Gastroenterology and Hepatology.

Pediatric nonalcoholic fatty liver disease-associated hospitalizations increased over time with higher rates among Hispanic adolescent boys, according to study results.

Patients with nonalcoholic fatty liver disease and liver-involved fibrosis frequently had a cholestatic pattern that increased the risk for liver-related events, according to a presentation at The Liver Meeting Digital Experience.

The temporal change rate of proton density fat fraction and liver stiffness measurement are promising predictors for those at high risk for rapid clinical progression and may improve patient management in those with nonalcoholic fatty liver disease.